The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
Currently no genomic signature exists to distinguish men most likely to progress on adjuvant androgen deprivation therapy (ADT) after radical prostatectomy (RP) for high risk prostate cancer. Mayo Clinic researchers developed and validated a gene expression signature to predict response to postoperative ADT. A training set consisting of 284 RP patients was established after 1:1 propensity score matching metastasis between adjuvant-ADT(a-ADT) treated and no-ADT treated groups. An ADT Response Signature (ADT-RS) was identified from neuroendocrine and AR-signaling related genes. Two independent cohorts were used to form three separate data sets for validation. The primary endpoint of the analysis was postoperative metastasis. Patients with High ADT-RS benefited from a-ADT. In combination with prognostic risk factors, use of ADT-RS may thus allow for identification of ADT-responsive tumors that may benefit most from early androgen blockade after RP. The study was published in Clinical Cancer Research.